Persistent Fetal Circulation Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRS030 MIFTS: 49	Persistent Fetal Circulation Syndrome Categories: Cardiovascular diseases, Fetal diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Persistent Fetal Circulation Syndrome

MalaCards integrated aliases for Persistent Fetal Circulation Syndrome:

Name: Persistent Fetal Circulation Syndrome ¹¹ ²⁸ ⁴³ ¹⁴ ¹⁶ ⁷¹ ³³

Persistent Fetal Circulation ¹¹ ⁷⁵ ³¹ ³³

Fetal Circulation ¹¹ ¹⁴ ³³

Persistent Pulmonary Hypertension of the Newborn ¹¹ ³³

Congenital Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins ¹¹

Pphn - [persistent Pulmonary Hypertension of the Newborn] ³³

Pfc - [persistent Fetal Circulation] Syndrome ³³

Primary Pulmonary Hypertension of Newborn ³³

Persistent Foetal Circulation Syndrome ¹¹

Newborn Pulmonary Hypertension ³³

Persistent Foetal Circulation ¹¹

Classifications:

MalaCards categories:
Global: Fetal diseases
Anatomical: Cardiovascular diseases Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain conditions originating in the perinatal period

Respiratory and cardiovascular disorders specific to the perinatal period

Cardiovascular disorders originating in the perinatal period

Persistent fetal circulation

ICD11: ³³

Certain conditions originating in the perinatal period

Cardiovascular disorders present in the perinatal or neonatal period

Persistent pulmonary hypertension of the newborn

External Ids:

Disease Ontology ¹¹ DOID:13042

ICD9CM ³⁴ 747.83

MeSH ⁴³ D010547

NCIt ⁴⁹ C85006

SNOMED-CT ⁶⁸ 35604006

ICD10 ³¹ P29.3

EFO ¹⁶ EFO_1001103

ICD11 ³³ 346808536

UMLS ⁷¹ C0031190

Sources

Summaries for Persistent Fetal Circulation Syndrome

MalaCards based summary: Persistent Fetal Circulation Syndrome, also known as persistent fetal circulation, is related to congestive heart failure and placental insufficiency. An important gene associated with Persistent Fetal Circulation Syndrome is MIR517A (MicroRNA 517a), and among its related pathways/superpathways are Signal Transduction and Peptide hormone metabolism. The drugs Adenosine and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include heart, placenta and brain, and related phenotypes are homeostasis/metabolism and renal/urinary system

Wikipedia: ⁷⁵ Persistent fetal circulation is a condition caused by a failure in the systemic circulation and... more...

Sources

Related Diseases for Persistent Fetal Circulation Syndrome

Diseases related to Persistent Fetal Circulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)

#	Related Disease	Score	Top Affiliating Genes
1	congestive heart failure	30.9	PDE5A INS IL6 EDN1 ALB
2	placental insufficiency	30.8	PGF LEP IL6
3	hypokalemia	30.8	POMC INS HSD11B2 ALB
4	cerebral palsy	30.8	OXT NOS3 LEP IL6 IGF1 ALB
5	eclampsia	30.8	PGF OXT NOS3 IL6 EDN1 ALB
6	graves disease 1	30.7	POMC INS ALB
7	tricuspid valve insufficiency	30.7	PDE5A EDN1 ALB
8	urinary tract infection	30.7	INS IL6 ALB
9	aspiration pneumonia	30.6	POMC INS IL6 ALB
10	asphyxia neonatorum	30.6	OXT INS IL6 ALB
11	severe pre-eclampsia	30.5	PGF OXT MIR517A LEP
12	interstitial lung disease	30.5	MIR21 IL6 IGF1 EDN1
13	beta-thalassemia	30.5	LEP INS IL6 IGF1
14	preterm premature rupture of the membranes	30.5	PGF OXT IL6
15	meconium aspiration syndrome	30.5	PDE5A OXT IL6 EDN1
16	stroke, ischemic	30.4	NOS3 MIR21 INS IL6 ALB
17	attention deficit-hyperactivity disorder	30.4	POMC OXT LEP INS IL6
18	ischemia	30.4	PGF PDE5A NOS3 MIR21 IL6 EDN1
19	oligohydramnios	30.4	PGF OXT MIR517A EDN1 ALB
20	hypoglycemia	30.3	POMC OXT LEP INS IGF1 ALB
21	respiratory failure	30.3	MIR21 INS IL6 ALB
22	inherited metabolic disorder	30.3	MIR21 LEP INS IL6 IGF1 ALB
23	hellp syndrome	30.3	PGF LEP IL6 HSD11B2 EDN1
24	pre-eclampsia	30.3	PGF PDE5A OXT NOS3 LEP INS
25	vascular disease	30.2	PDE5A NOS3 MIR21 LEP INS IL6
26	placental abruption	30.2	PGF OXT MIR517A
27	pulmonary hypertension	30.2	PGF PDE5A NOS3 MIR21 IL6 EDN1
28	hypertrophic cardiomyopathy	30.2	NOS3 MIR21 INS IL6 IGF1 EDN1
29	aspiration pneumonitis	30.2	OXT IL6 ALB
30	choriocarcinoma	30.2	PGF HSD11B2 CSH2 CSH1
31	gestational diabetes	30.1	PGF NOS3 LEP INS IL6 IGF1
32	patent ductus arteriosus 1	30.1	PDE5A INS IL6 IGF1 EDN1 ALB
33	polyhydramnios	30.1	OXT INS EDN1
34	leptin deficiency or dysfunction	30.1	POMC OXT LEP INS IL6 IGF1
35	patent foramen ovale	30.0	PDE5A INS IL6 EDN1 ALB
36	deficiency anemia	30.0	OXT LEP INS IL6 IGF1 ALB
37	arteriosclerosis	30.0	MIR21 INS IL6 EDN1
38	hyperinsulinism	30.0	LEP INS IGF1 EDN1
39	pain agnosia	30.0	POMC OXT INS IL6 ALB
40	type 1 diabetes mellitus	29.9	LEP INS IL6 IGF1 HSD11B2 ALB
41	skin disease	29.7	POMC MIR21 INS IL6 IGF1 ALB
42	anxiety	29.7	POMC OXT LEP INS IL6 IGF1
43	lipoprotein quantitative trait locus	29.7	PGF PDE5A NOS3 MIR21 INS IL6
44	heart disease	29.7	PGF PDE5A NOS3 MIR21 INS IL6
45	chronic kidney disease	29.6	NOS3 MIR21 LEP INS IL6 IGF1
46	type 2 diabetes mellitus	29.2	POMC PGF PDE5A NOS3 MIR21 LEP
47	diabetes mellitus	29.2	POMC PGF PDE5A OXT NOS3 MIR21
48	hypertension, essential	28.8	SLC1A7 POMC PGF PDE5A OXT NOS3
49	alveolar capillary dysplasia with misalignment of pulmonary veins	11.4
50	testicular trophoblastic tumor	10.5	CSH2 CSH1

Graphical network of the top 20 diseases related to Persistent Fetal Circulation Syndrome:

Sources

Symptoms & Phenotypes for Persistent Fetal Circulation Syndrome

MGI Mouse Phenotypes related to Persistent Fetal Circulation Syndrome:

⁴⁵ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.34	ALB CSH1 CSH2 EDN1 FCGRT HSD11B2
2	renal/urinary system	MP:0005367	10.29	ALB CSH1 CSH2 EDN1 HSD11B2 IGF1
3	growth/size/body region	MP:0005378	10.25	CSH1 CSH2 EDN1 IGF1 IL6 INS
4	adipose tissue	MP:0005375	10.16	CSH1 CSH2 IGF1 IL6 INS LEP
5	liver/biliary system	MP:0005370	10.13	ALB CSH1 CSH2 IL6 INS LEP
6	endocrine/exocrine gland	MP:0005379	10.11	ALB CSH1 CSH2 EDN1 IGF1 IL6
7	muscle	MP:0005369	10.1	ALB EDN1 HSD11B2 IGF1 IL6 INS
8	neoplasm	MP:0002006	10.07	ALB HSD11B2 IGF1 IL6 LEP PGF
9	cardiovascular system	MP:0005385	10.07	ALB CSH1 CSH2 EDN1 HSD11B2 IGF1
10	digestive/alimentary	MP:0005381	9.97	ALB EDN1 HSD11B2 IL6 INS LEP
11	immune system	MP:0005387	9.93	ALB CSH1 CSH2 FCGRT IGF1 IL6
12	respiratory system	MP:0005388	9.56	CSH1 CSH2 IGF1 IL6 LEP NOS3
13	mortality/aging	MP:0010768	9.5	ALB CSH1 CSH2 EDN1 FCGRT HSD11B2

Sources

Drugs & Therapeutics for Persistent Fetal Circulation Syndrome

Drugs for Persistent Fetal Circulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Adenosine

Approved, Investigational

Phase 4

58-61-7

60961

Pharmaceutical Solutions

Phase 4

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 3

139755-83-2, 171599-83-0

5212 135398744

Racephedrine

Approved, Experimental

Phase 2, Phase 3

299-42-3, 90-82-4, 90-81-3

5032 9294 7028

Phenylephrine

Approved

Phase 2, Phase 3

59-42-7

6041

Oxymetazoline

Approved, Investigational

Phase 2, Phase 3

1491-59-4

4636

Bosentan

Approved, Investigational

Phase 3

147536-97-8

104865

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Cardiotonic Agents

Phase 2, Phase 3

Phosphodiesterase Inhibitors

Phase 3

Phosphodiesterase 5 Inhibitors

Phase 3

Citrate

Phase 3

Central Nervous System Stimulants

Phase 2, Phase 3

Adrenergic alpha-Agonists

Phase 2, Phase 3

Adrenergic Agonists

Phase 2, Phase 3

Adrenergic Agents

Phase 2, Phase 3

Vasoconstrictor Agents

Phase 2, Phase 3

Mydriatics

Phase 2, Phase 3

Sympathomimetics

Phase 2, Phase 3

Nasal Decongestants

Phase 2, Phase 3

Antihypertensive Agents

Phase 3

Endothelin Receptor Antagonists

Phase 3

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 1, Phase 2

7487-88-9

Epoprostenol

Approved

Phase 2

61849-14-7, 35121-78-9

5282411

Treprostinil

Approved, Investigational

Phase 2

81846-19-7

6918140

Tezosentan

Investigational

Phase 2

180384-57-0

Hormones

Phase 1, Phase 2

Anti-Arrhythmia Agents

Phase 1, Phase 2

Calcium, Dietary

Phase 1, Phase 2

Anticonvulsants

Phase 1, Phase 2

Anesthetics

Phase 1, Phase 2

calcium channel blockers

Phase 1, Phase 2

Analgesics

Phase 1, Phase 2

Tocolytic Agents

Phase 1, Phase 2

Antidepressive Agents, Tricyclic

Phase 2

Calcium

Nutraceutical

Phase 1, Phase 2

7440-70-2

271

Metaraminol

Approved, Investigational

54-49-9

5906

Carbon monoxide

Approved, Investigational

630-08-0

281

Tadalafil

Approved, Investigational

171596-29-5

110635

Milrinone

Approved

78415-72-2

4197

Immunoglobulins

Antibodies

Liver Extracts

Phosphodiesterase 3 Inhibitors

Natriuretic Peptide, Brain

Interventional clinical trials:

(show all 34)

#	Name	Status	NCT ID	Phase	Drugs
1	Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation	Completed	NCT00732537	Phase 4	inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
2	Oral Sildenafil in Persistent Pulmonary Hypertension of Neonates Secondary to Meconium Aspiration Syndrome: A Randomized Placebo Controlled Trial	Completed	NCT01757782	Phase 4	Oral Sildenafil;Placebo (distilled water)
3	Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure	Withdrawn	NCT01891500	Phase 4	Inhaled nitric oxide;Nitrogen Gas;Crossover iNO
4	Early Combined Use of Inhaled Nitric Oxide and Oral Sildenafil on the Outcome of Pulmonary Hypertension in New Born Infants	Unknown status	NCT01558466	Phase 3	Sildenafil;diluent
5	A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT	Completed	NCT01720524	Phase 3	placebo;iv sildenafil
6	Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study	Completed	NCT03047109	Phase 2, Phase 3	Phenylephrine;Ephedrine
7	The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure	Terminated	NCT00005776	Phase 3	Inhaled nitric oxide;Placebo
8	Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure	Terminated	NCT00005773	Phase 3	Inhaled Nitric Oxide;Standard iNO therapy
9	Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)	Terminated	NCT01389856	Phase 3	Bosentan;Matching placebo
10	Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn	Completed	NCT04328636	Phase 1, Phase 2	Nebulized Magnesium Sulfate;Intravenous Magnesium Sulfate
11	Milrinone in Congenital Diaphragmatic Hernia	Recruiting	NCT02951130	Phase 2	Milrinone;Placebo (5% Dextrose)
12	Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study	Recruiting	NCT02261883	Phase 2	IV Remodulin;Placebo
13	Effectiveness of Nebulized Magnesium Sulfate Combined With Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn	Recruiting	NCT04898114	Phase 1, Phase 2	Magnesium sulfate;Sildenafil Citrate
14	A Single Arm Single Centre Study To Investigate Safety And Efficacy Of Sildenafil In Near Term And Term Newborns With Persistent Pulmonary Hypertension Of The Newborn (PPHN)	Terminated	NCT01069861	Phase 2	sildanefil
15	A Randomized, Double Blind, Placebo-controlled Pilot Study of the Safety and Effective Dosing of Inhaled Iloprost in Pediatric Patients With Pulmonary Hypertension Treated With Inhaled Nitric Oxide	Withdrawn	NCT00981591	Phase 1, Phase 2	Iloprost;Placebo
16	An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN)	Withdrawn	NCT01360671	Phase 2	Sildenafil
17	Pharmacokinetics of Sildenafil in Premature Infants	Completed	NCT01670136	Phase 1	1 dose of sildenafil
18	Doppler Ultrasonographic Assessment of Fetal Internal Thoracic Artery Indexes	Unknown status	NCT04686240
19	Examination of Perfusion Index in Term and Preterm Newborns Through Plethismography	Unknown status	NCT02380040
20	Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension	Unknown status	NCT01373749		NO inhalation;NO inhalation continued with sildenafil
21	Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean	Unknown status	NCT02245191		Ephedrine;Phenylephrine;Metaraminol
22	NO Need to Ventilate: A Trial of Non-invasive iNO in Persistent Pulmonary Hypertension of the Newborn	Completed	NCT00139217		iNO
23	Risk Factors for Pulmonary Hypertension of the Newborn	Completed	NCT00005497
24	NEURodevelopmental Outcome in Children Between One and Five Years After Persistent Pulmonary Hypertension Of the Newborn	Completed	NCT04841070
25	Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO)	Completed	NCT00371241
26	Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children	Completed	NCT00005323
27	Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study	Completed	NCT01203423
28	A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO	Completed	NCT02940327
29	Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)	Recruiting	NCT00710177
30	Assessment of Effects of Maternal Smoking on Fetal Liver Circulation With Ultrasonography	Active, not recruiting	NCT04721782
31	Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension (POST-IT)	Enrolling by invitation	NCT04938167
32	Population Pharmacokinetics and Dosage Individualization of Bosentan, Sildenafil and Tadalafil in Persistent Pulmonary Hypertension of the Newborn	Not yet recruiting	NCT04379180		Bosentan Tablets;Sildenafil Tablet;Tadalafil Tablets
33	Clinical Significance of N-Terminal Pro-Brain Natriuretic Peptide Levels in Persistent Pulmonary Hypertension	Terminated	NCT00443859
34	Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention	Terminated	NCT01088997		Milrinone Lactate

Search NIH Clinical Center for Persistent Fetal Circulation Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Tolazoline

Tolazoline Hydrochloride

Cochrane evidence based reviews: persistent fetal circulation syndrome

Sources

Genetic Tests for Persistent Fetal Circulation Syndrome

Genetic tests related to Persistent Fetal Circulation Syndrome:

#	Genetic test	Affiliating Genes
1	Persistent Fetal Circulation Syndrome ²⁸

Sources

Anatomical Context for Persistent Fetal Circulation Syndrome

Organs/tissues related to Persistent Fetal Circulation Syndrome:

MalaCards : Heart, Placenta, Brain, Fetal Liver, Liver, Lung, Endothelial

Sources

Publications for Persistent Fetal Circulation Syndrome

Articles related to Persistent Fetal Circulation Syndrome:

(show top 50) (show all 3376)

#	Title	Authors	PMID	Year
1	Ex vivo perfusion of the human placenta to investigate pregnancy pathologies. ⁶²	Zabel RR...Jones S	36343527	2022
2	Maternal, neonatal and placental characteristics of SARS-CoV-2 positive mothers. ⁶²	Zhang P...Lederman S	33645395	2022
3	Implications of placentation type on species-specific colostrum properties in mammals. ⁶²	Bigler NA...Gross JJ	36048628	2022
4	Nalbuphine: a candidate for treatment of women overwhelmed with sudden, intense labor pain? ⁶²	Schoppmann S...Simoes-Wust AP	33899644	2022
5	Amniotic fluid index measurements in the second and third trimester and correlation to fetal biometric parameters - new reference based on a big retrospective data. ⁶²	Kirshenbaum M...Katorza E	34470112	2022
6	Transfer of Zolpidem to Cord Blood and Breast Milk: A Case Series Evaluating Zolpidem Serum Levels and Outcomes in Birth and Suckling Infants. ⁶²	Saito J...Murashima A	36301249	2022
7	Fetal Development in Anatomical Preparations of Ruysch and the Meckels in Comparison. ⁶²	Kosenko O...Steger F	36429620	2022
8	Nanoparticle-mediated transgene expression of insulin-like growth factor 1 in the growth restricted guinea pig placenta increases placenta nutrient transporter expression and fetal glucose concentrations. ⁶²	Wilson RL...Jones HN	36094907	2022
9	Experimental human placental models for studying uptake, transport and toxicity of micro- and nanoplastics. ⁶²	Dusza HM...Vahakangas KH	36417947	2022
10	Thyroid hormones: Metabolism and transportation in the fetoplacental unit. ⁶²	Zuniga LFF...Pustovrh MC	36208482	2022
11	Asymmetrical transport of thyroxine across human term placenta. ⁶²	Chen Z...Meima ME	36416258	2022
12	Placental proteins with predicted roles in fetal development decrease in premature infants. ⁶²	Schreiner C...Jansson T	35132128	2022
13	The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1). ⁶²	El-Khuffash A...Dempsey E	36385642	2022
14	Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial. ⁶²	Imam SS...Saleh GA	35881893	2022
15	Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons: an almost 5-year retrospective cohort study. ⁶²	Xu T...Wang X	36335293	2022
16	Perinatal changes of right ventricle-pulmonary artery coupling and its value in predicting persistent pulmonary hypertension of the newborn. ⁶²	Zhang J...Wu XC	35852214	2022
17	Transposition With Hypertrophic Cardiomyopathy and Persistent Pulmonary Hypertension of the Newborn. ⁶²	Brooks BA...Yurasek GK	35604788	2022
18	Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child. ⁶²	Lebin LG...Novick AM	36181572	2022
19	Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn. ⁶²	Verma S...Randis TM	33477175	2022
20	The Relationship Between Placental Pathology and Neurodevelopmental Outcomes in Complex Congenital Heart Disease. ⁶²	Segar DE...Cohen S	36201029	2022
21	Impact of Changes in Early Respiratory Support Management on Respiratory Outcomes of Preterm Infants. ⁶²	Xie L...Gao W	35764345	2022
22	Analgesia during Parturition in Domestic Animals: Perspectives and Controversies on Its Use. ⁶²	Mota-Rojas D...Whittaker AL	36230426	2022
23	Sildenafil improves pulmonary vascular remodeling in a rat model of persistent pulmonary hypertension of the newborn. ⁶²	Kang L...Li X	36198097	2022
24	Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. ⁶²	Turner JM...Kumar S	35352868	2022
25	Volumetric Fetal Flow Imaging With Magnetic Resonance Imaging. ⁶²	Goolaub DS...Macgowan CK	35604966	2022
26	Maternal exposure to ambient black carbon particles and their presence in maternal and fetal circulation and organs: an analysis of two independent population-based observational studies. ⁶²	Bongaerts E...Nawrot TS	36208643	2022
27	Fetal Myocardial Expression of GLUT1: Roles of BPA Exposure and Cord Blood Exosomes in a Rat Model. ⁶²	Ermini L...Ietta F	36291063	2022
28	Maternal Delta-9-Tetrahydrocannabinol Exposure Induces Abnormalities of the Developing Heart in Mice. ⁶²	Robinson GI...Feng Q	36255470	2022
29	Is It Time to Redefine Fetal Decelerations in Cardiotocography? ⁶²	Xodo S...Londero AP	36294689	2022
30	Relationship of ANGPTL6 With Neonatal Glucose Homeostasis and Fat Mass Is Disrupted in Gestational Diabetic Pregnancies. ⁶²	Valencia-Martinez A...Ortega-Senovilla H	35876300	2022
31	Iron transport across the human placenta is regulated by hepcidin. ⁶²	McDonald EA...Friedman JF	33069164	2022
32	Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension. ⁶²	Cookson MW...Mandell EW	35688685	2022
33	Persistent pulmonary hypertension of the newborn: Historical perspectives. ⁶²	Donn SM	35181257	2022
34	The interplay between pressure, flow, and resistance in neonatal pulmonary hypertension. ⁶²	Jones CB...Crossland DS	35787350	2022
35	Impact of hypertensive disorders of pregnancy on respiratory outcomes in extremely and very preterm infants: A population-based study in Japan. ⁶²	Ushida T...Neonatal Research Network of Japan	35750024	2022
36	Long term outcome of babies with pulmonary hypertension. ⁶²	Durward A...Macrae D	36031529	2022
37	Veno-arterial extracorporeal membrane oxygenation for treatment of persistent pulmonary hypertension of the newborn. ⁶²	Song S...Lee NH	36028404	2022
38	Pulmonary hypertension in the newborn- etiology and pathogenesis. ⁶²	Sankaran D...Lakshminrusimha S	35963740	2022
39	Pulmonary hypertension and oxidative stress: Where is the link? ⁶²	Rawat M...Vento M	35473693	2022
40	Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn. ⁶²	Miller TF...Davis JM	35469712	2022
41	Hyperandrogenism diminishes maternal-fetal fatty acid transport by increasing FABP4-mediated placental lipid accumulation†. ⁶²	Gopalakrishnan K...Kumar S	35357467	2022
42	Ligamentum arteriosum: Muscular and contractile. ⁶²	Mensah B	36054486	2022
43	Echocardiographic Features of the Ductus Arteriosus and the Foramen Ovale in a Hospital-Based Population of Neonatal Foals. ⁶²	De Lange L...Decloedt A	36077962	2022
44	Study protocol for a randomized trial on timely delivery versus expectant management in late preterm small for gestational age pregnancies with an abnormal umbilicocerebral ratio (UCR): the DRIGITAT study. ⁶²	Smies M...Ganzevoort W	35915472	2022
45	Effects of prenatal opioid and alcohol exposures on immune and serotonin factors in human placenta. ⁶²	Ruyak SL...Bakhireva LN	35364108	2022
46	[Application of extracorporeal membrane oxygenation in the treatment of persistent pulmonary hypertension of the newborn]. ⁶²	Chen YL...Zhang MG	35894194	2022
47	Ductus arteriosus: more than just the patent ductus arteriosus. ⁶²	Buckland CC...Culham JAG	35809133	2022
48	RE: Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of persistent pulmonary hypertension of the newborn (PPHN): A multicenter, randomized, placebo-controlled trial. ⁶²	Cochius-den Otter S...de Winter BCM	35447124	2022
49	Persistence of persistent pulmonary hypertension of the newborn: A case of de novo TBX4 variant. ⁶²	Tsoi SM...Keller RL	35874850	2022
50	Possible association between a polymorphism of EPAS1 gene and persistent pulmonary hypertension of the newborn: a case-control study. ⁶²	Nakwan N...Charalsawadi C	34678164	2022

Sources

Genes for Persistent Fetal Circulation Syndrome

Genes related to Persistent Fetal Circulation Syndrome (0 elite genes):

(show all 36)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR517A	MicroRNA 517a	RNA Gene	7.27	DISEASES inferred ¹⁴ ¹⁴
2	FCGRT	Fc Gamma Receptor And Transporter	Protein Coding	7.27	DISEASES inferred ¹⁴
3	CSH1	Chorionic Somatomammotropin Hormone 1	Protein Coding	6.67	DISEASES inferred ¹⁴
4	CSH2	Chorionic Somatomammotropin Hormone 2	Protein Coding	6.58	DISEASES inferred ¹⁴
5	HSD11B2	Hydroxysteroid 11-Beta Dehydrogenase 2	Protein Coding	6.57	DISEASES inferred ¹⁴
6	EDN1	Endothelin 1	Protein Coding	6.38	DISEASES inferred ¹⁴
7	NOS3	Nitric Oxide Synthase 3	Protein Coding	6.23	DISEASES inferred ¹⁴
8	PGF	Placental Growth Factor	Protein Coding	6.21	DISEASES inferred ¹⁴
9	PDE5A	Phosphodiesterase 5A	Protein Coding	6.19	DISEASES inferred ¹⁴
10	INS	Insulin	Protein Coding	6.17	DISEASES inferred ¹⁴
11	LEP	Leptin	Protein Coding	6.1	DISEASES inferred ¹⁴
12	IL6	Interleukin 6	Protein Coding	6.05	DISEASES inferred ¹⁴
13	ALB	Albumin	Protein Coding	6.01	DISEASES inferred ¹⁴
14	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	5.96	DISEASES inferred ¹⁴
15	SLC27A4	Solute Carrier Family 27 Member 4	Protein Coding	5.9	DISEASES inferred ¹⁴
16	POMC	Proopiomelanocortin	Protein Coding	5.9	DISEASES inferred ¹⁴
17	SLC1A7	Solute Carrier Family 1 Member 7	Protein Coding	5.9	DISEASES inferred ¹⁴
18	SLC38A4	Solute Carrier Family 38 Member 4	Protein Coding	5.88	DISEASES inferred ¹⁴
19	MIR21	MicroRNA 21	RNA Gene	5.88	DISEASES inferred ¹⁴ ¹⁴
20	IGF1	Insulin Like Growth Factor 1	Protein Coding	5.88	DISEASES inferred ¹⁴
21	CRH	Corticotropin Releasing Hormone	Protein Coding	5.86	DISEASES inferred ¹⁴
22	SLC7A8	Solute Carrier Family 7 Member 8	Protein Coding	5.85	DISEASES inferred ¹⁴
23	IGF2	Insulin Like Growth Factor 2	Protein Coding	5.8	DISEASES inferred ¹⁴
24	SLC22A11	Solute Carrier Family 22 Member 11	Protein Coding	5.78	DISEASES inferred ¹⁴
25	ABCG2	ATP Binding Cassette Subfamily G Member 2 (Junior Blood Group)	Protein Coding	5.78	DISEASES inferred ¹⁴
26	TNF	Tumor Necrosis Factor	Protein Coding	5.77	DISEASES inferred ¹⁴
27	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.75	DISEASES inferred ¹⁴
28	SLC2A3	Solute Carrier Family 2 Member 3	Protein Coding	5.72	DISEASES inferred ¹⁴
29	SLC38A1	Solute Carrier Family 38 Member 1	Protein Coding	5.7	DISEASES inferred ¹⁴
30	GCM1	Glial Cells Missing Transcription Factor 1	Protein Coding	5.7	DISEASES inferred ¹⁴
31	SLC27A1	Solute Carrier Family 27 Member 1	Protein Coding	5.68	DISEASES inferred ¹⁴
32	SLC27A6	Solute Carrier Family 27 Member 6	Protein Coding	5.68	DISEASES inferred ¹⁴
33	SLC38A2	Solute Carrier Family 38 Member 2	Protein Coding	5.66	DISEASES inferred ¹⁴
34	EDNRA	Endothelin Receptor Type A	Protein Coding	5.64	DISEASES inferred ¹⁴
35	IL1B	Interleukin 1 Beta	Protein Coding	5.64	DISEASES inferred ¹⁴
36	HLA-G	Major Histocompatibility Complex, Class I, G	Protein Coding	5.61	DISEASES inferred ¹⁴

Sources

Variations for Persistent Fetal Circulation Syndrome

Sources

Expression for Persistent Fetal Circulation Syndrome

Search GEO for disease gene expression data for Persistent Fetal Circulation Syndrome.

Sources

Pathways for Persistent Fetal Circulation Syndrome

Pathways related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.52	EDN1 IGF1 IL6 INS LEP NOS3
2	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.01	POMC LEP INS IGF1
3	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	11.97	PGF NOS3 INS IL6 IGF1 CSH2
4	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.79	INS IL6 IGF1 ALB
5	Adipogenesis ⁷⁴	11.74	LEP INS IL6 IGF1
6	Clock-controlled autophagy in bone metabolism ⁷⁴	11.62	LEP IL6 IGF1
7	Prostaglandin synthesis and regulation ⁷⁴ Show member pathways Defective TBXAS1 causes GHDD ⁶⁶ Eicosanoid metabolism via cyclooxygenases (COX) ⁷⁴ Ibuprofen Pathway, Pharmacodynamics ⁶⁰	11.59	NOS3 HSD11B2 EDN1
8	Lung fibrosis ⁷⁴	11.49	IL6 IGF1 EDN1
9	Prader-Willi and Angelman syndrome ⁷⁴	11.45	POMC OXT INS
10	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.43	LEP INS IL6 IGF1
11	Pluripotent stem cell differentiation pathway ⁷⁴	11.31	INS IL6 IGF1
12	Nonalcoholic fatty liver disease ⁷⁴	11.27	LEP INS IL6
13	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	10.91	POMC LEP EDN1
14	NO-dependent CFTR activation (normal and CF) ²²	10.66	PDE5A NOS3
15	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.43	POMC LEP INS

Sources

GO Terms for Persistent Fetal Circulation Syndrome

Cellular components related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.98	POMC PGF OXT LEP INS IL6
2	extracellular space	GO:0005615	9.72	ALB CSH1 CSH2 EDN1 FCGRT IGF1

Biological processes related to Persistent Fetal Circulation Syndrome according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.42	CSH1 CSH2 IGF1 IL6 INS LEP
2	positive regulation of cell population proliferation	GO:0008284	10.15	PGF MIR21 LEP INS IL6 IGF1
3	glucose homeostasis	GO:0042593	10.11	IL6 INS LEP POMC
4	positive regulation of protein kinase B signaling	GO:0051897	10.07	MIR21 LEP INS IGF1
5	female pregnancy	GO:0007565	10.06	HSD11B2 LEP OXT PGF
6	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.98	MIR21 LEP INS IGF1
7	positive regulation of mitotic nuclear division	GO:0045840	9.97	INS IGF1 EDN1
8	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.96	MIR21 IGF1 EDN1
9	regulation of blood pressure	GO:0008217	9.95	POMC NOS3 LEP EDN1
10	response to activity	GO:0014823	9.92	EDN1 IL6 LEP OXT
11	positive regulation of cell growth involved in cardiac muscle cell development	GO:0061051	9.89	IGF1 EDN1
12	bone mineralization involved in bone maturation	GO:0035630	9.88	LEP IGF1
13	activation of protein kinase B activity	GO:0032148	9.88	MIR21 INS IGF1
14	regulation of systemic arterial blood pressure by endothelin	GO:0003100	9.87	NOS3 EDN1
15	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.76	MIR21 IL6
16	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	9.76	LEP IL6 CSH2 CSH1
17	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.71	MIR21 IGF1
18	negative regulation of smooth muscle cell apoptotic process	GO:0034392	9.65	MIR21 IGF1 EDN1
19	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.65	LEP IL6 IGF1 CSH2 CSH1
20	positive regulation of cardiac muscle hypertrophy	GO:0010613	9.17	PDE5A MIR21 IGF1 EDN1